Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,918 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1792
- Phase 1/Phase 2478
- Phase 3345
- Phase 4126
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia281
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,918 total
- NCT06737081RecruitingPhase 2
Study of an experimental anemia treatment for chemotherapy patients
This study tests a new medication (SAL-0951) for treating low red blood cell counts (anemia) caused by chemotherapy in people with certain types of cancer that are not curable. It may help improve energy and reduce the need for blood transfusions.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06731699RecruitingPhase 1
Testing FD-001 for blood cancers that returned or didn't respond
This trial tests a new drug, FD-001, for people with certain blood cancers (like leukemia, lymphoma, or myeloma) that have come back or stopped responding to standard treatments. The goal is to see if the drug is safe and how well it might work.
Chengdu, SichuanAges 18–80 - NCT06558253RecruitingPhase 1
Coenzyme I for blood recovery after cord blood transplant
This trial tests whether a drug called Coenzyme I (given by injection) can help your blood cells recover faster after a cord blood transplant for blood cancer. It is for people who are getting this type of transplant for the first time and are in fairly good health otherwise.
Hefei, AnhuiAges 18–60 - NCT05806346Recruiting
TXA dosing for heart surgery patients on bypass
This trial studies whether giving tranexamic acid (TXA) based on patient needs during heart surgery works better than a one-size-fits-all approach. It may help reduce bleeding during surgery, while monitoring for clotting-related side effects.
SeoulAges 19 years+ - NCT06739265RecruitingPhase 1/Phase 2
Golidocitinib plus CHOP for new T-cell lymphoma
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
BeijingAges 18–70 - NCT06362967RecruitingPhase 2
Lowering high antibodies before stem cell transplant
This trial tests a special treatment to lower high levels of anti-HLA antibodies before a stem cell transplant. The goal is to help the transplant succeed and reduce the risk of rejection.
Hefei, AnhuiAges 14–60 - NCT06561854RecruitingPhase 3
Comparing multiple myeloma treatment with and without dexamethasone
This trial tests whether adding dexamethasone to an antibody-based combination therapy works better for multiple myeloma that has come back after previous treatments. If you have had 1 to 3 prior therapies and are eligible for one of two standard drug regimens, this study may help find the best approach for you.
ParisAges 18 years+ - NCT07554898RecruitingPhase 2
Low-dose Radiation Plus Orelabrutinib for Early-stage MALT Lymphoma
This trial tests combining very low-dose radiation therapy with a targeted drug called orelabrutinib (a type of cancer-fighting protein inhibitor) as a first treatment for early-stage MALT lymphoma, a slow-growing blood cancer. The goal is to see if this combination can shrink or control the cancer with fewer side effects than standard chemotherapy.
Hangzhou, ZhejiangAges 18 years+ - NCT07551583RecruitingPhase 2
Nivolumab plus chemotherapy for early-stage Hodgkin lymphoma in young people
This study tests a combination of a newer immunotherapy drug (nivolumab) with standard chemotherapy (AVD) in children, teens, and young adults with newly diagnosed, early-stage Hodgkin lymphoma—a blood cancer affecting lymph nodes. The goal is to see if adding immunotherapy improves outcomes while being tolerable for this age group.
Houston, TexasAges 2–21 - NCT07555470RecruitingPhase 2
New drugs for follicular lymphoma: mosunetuzumab and zeprumetostat
This study tests two new drugs combined together to treat follicular lymphoma (a slow-growing blood cancer). The trial enrolls patients who have never been treated, those with limited disease who want active treatment, and those whose cancer came back or didn't respond to prior therapy.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07559331RecruitingPhase 3
Dexamethasone plus Orelabrutinib for newly diagnosed immune thrombocytopenia
This trial tests whether adding a drug called orelabrutinib to high-dose dexamethasone (a steroid) works better than dexamethasone alone for treating newly diagnosed immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing very low blood counts. The goal is to see if the combination helps raise your platelet count and prevents bleeding.
Jinan, ShandongAges 18–80 - NCT07558538RecruitingEarly Phase 1
Inhaled Growth Factor Treatment for Severe Lung Failure
This early-stage trial tests whether an inhaled medication called recombinant human keratinocyte growth factor-2 (rh-KGF-2) can help patients with acute respiratory distress syndrome (ARDS)—a serious condition where the lungs cannot deliver enough oxygen to the blood. The drug is designed to help repair lung tissue damage.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07553572Recruiting
Smartphone app to track cancer symptoms during treatment
This study tests a smartphone application designed to help you monitor and manage side effects and symptoms while you're receiving chemotherapy or other systemic treatment for breast cancer, colorectal cancer, or lymphoma. The app may help your doctors catch problems early and support you throughout your treatment.
Boston, MassachusettsAges 18 years+ - NCT07558317Recruiting
Resistance Exercise for Lower Leg Swelling
This study tests whether strength-training exercises can help reduce swelling in the lower leg caused by lymphedema. You'll wear compression garments as usual and add supervised resistance exercises to see if they improve your symptoms and quality of life.
HerlevAges 18 years+ - NCT07555431RecruitingPhase 2
Dolutegravir alone versus with tenofovir for HTLV-1
This study tests whether adding tenofovir (an antiviral medication) to dolutegravir helps treat HTLV-1 infection better than dolutegravir alone. HTLV-1 is a virus that can cause serious health problems, and researchers want to find the most effective treatment combination.
Salvador, Estado de BahiaAges 18 years+ - NCT07556822RecruitingPhase 1
Testing HRS-3005 for Blood Cancers That Have Returned
This study tests a new drug called HRS-3005 in patients with B-cell blood cancers that have come back or stopped responding to prior treatment. The trial aims to find the right dose and understand how well the drug works and what side effects it causes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07551427RecruitingPhase 2
Testing TQ05105 for intermediate/high-risk myelofibrosis
This trial tests a new drug called TQ05105 to see if it can help people with a blood-marrow disease called myelofibrosis. The study focuses on patients whose condition is moderate to severe and measures how well the drug works and how safe it is.
Hefei, AnhuiAges 18 years+ - NCT07558915RecruitingPhase 1
Testing RO7851624 for Relapsed Multiple Myeloma
This Phase 1 trial tests a new drug called RO7851624 in patients whose multiple myeloma has come back or stopped responding to prior treatments. The goal is to understand how safe and effective this drug is.
Parkville, VictoriaAges 18 years+ - NCT07559474RecruitingPhase 1
Safety Study of INCB123667 in Adults With Liver Damage
This study tests how a new experimental medicine (INCB123667) works and is tolerated in adults with moderate to severe liver problems. Researchers want to understand how the body processes this drug and whether it's safe in people with liver dysfunction.
Chandler, ArizonaAges 18–80 - NCT07555938RecruitingPhase 3
New drug combination for previously treated multiple myeloma
This trial tests whether a new drug called cevostamab, combined with two existing myeloma drugs (pomalidomide and dexamethasone), works better than standard treatment for people whose myeloma has returned or stopped responding to prior therapy. You would receive this combination to see if it helps control your disease.
Duarte, CaliforniaAges 18 years+ - NCT06739759Recruiting
Preventing OHSS in PCOS women having ICSI
This trial tests a way to prevent a side effect called ovarian hyperstimulation syndrome (OHSS) in women with PCOS who are having ICSI (a type of IVF). The goal is to make fertility treatment safer for you.
GizaAges 19–42 - NCT05477589RecruitingPhase 3
Conditioning plan for kids with AML before stem cell transplant
This Phase 3 trial studies the best “conditioning” chemotherapy plan before an allogeneic stem cell transplant for children with AML. It may help improve outcomes by testing an approach for kids who are ready for transplant after relapse or specific high-risk features.
BrusselsAges Up to 18 years - NCT06026488Recruiting
Study of DLBCL by genetic subtype
This study looks at how different genetic types of diffuse large B-cell lymphoma (DLBCL) respond to treatment in real-world settings. It may help doctors understand which treatments work best for your specific subtype.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06332430RecruitingPhase 1
Injecting CAN2109 into tumors for solid cancers
This trial tests CAN2109, a drug injected directly into tumors. It is for people with advanced solid cancers that have not responded to standard treatments. The goal is to see if this approach can help control the disease.
Guangzhou, GuangdongAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,918 recruiting hematology studies from the U.S. registry right now, out of 7,266 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.